Albert S. Kim

Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan.

Journal: Bone

Published: May 05, 2026

Denosumab discontinuation and fracture risk: getting the balance right.

Journal: Internal medicine journal

Published: March 18, 2026

Hypophosphatemia across the lifespan.

Journal: JBMR plus

Published: September 02, 2025

Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: September 21, 2024

Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: September 14, 2024

Author response to: OSIN-D-24-00849 Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: July 24, 2024

A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: March 10, 2024

Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect.

Journal: Bone research

Published: January 10, 2024

Early protein C activation is reflective of burn injury severity and plays a critical role in inflammatory burden and patient outcomes.

Journal: Burns : journal of the International Society for Burn Injuries

Published: July 12, 2020

Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan.

Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan.

Denosumab discontinuation and fracture risk: getting the balance right.

Denosumab discontinuation and fracture risk: getting the balance right.

Hypophosphatemia across the lifespan.

Hypophosphatemia across the lifespan.

Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition.

Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition.

Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures.

Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures.

Author response to: OSIN-D-24-00849 Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Author response to: OSIN-D-24-00849 Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect.

Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect.

Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition.

Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition.

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.

New Insights Into Osteoclast Biology.

New Insights Into Osteoclast Biology.

Early protein C activation is reflective of burn injury severity and plays a critical role in inflammatory burden and patient outcomes.

Early protein C activation is reflective of burn injury severity and plays a critical role in inflammatory burden and patient outcomes.